Literature DB >> 20931169

[Somatoform disorders and functional somatic syndromes].

C Lahmann1, P Henningsen, A Dinkel.   

Abstract

Somatoform symptoms occur in the absence of clear organic pathology. Typically, such symptoms are long-lasting and disabling. Somatoform symptoms and disorders are highly prevalent in primary care. The course of somatoform disorders is mostly chronic, and remission rates are low. Multiple factors influence the development and perpetuation of somatoform disorders. Currently, there is strong debate about the classification of somatoform disorders, and it is very likely that there will be significant changes in the classification of somatoform disorders in the upcoming DSM-V. With regard to the psychotherapeutic treatment of somatoform disorders, there is empirical evidence for the efficacy of cognitive-behavioral as well as psychodynamic-interpersonal strategies. Pharmacotherapy plays a minor role, but it can be useful mainly in cases of comorbid depression or anxiety.

Entities:  

Mesh:

Year:  2010        PMID: 20931169     DOI: 10.1007/s00115-010-3056-y

Source DB:  PubMed          Journal:  Nervenarzt        ISSN: 0028-2804            Impact factor:   1.214


  27 in total

Review 1.  Towards positive diagnostic criteria: a systematic review of somatoform disorder diagnoses and suggestions for future classification.

Authors:  Katharina Voigt; Annabel Nagel; Björn Meyer; Gernot Langs; Christoph Braukhaus; Bernd Löwe
Journal:  J Psychosom Res       Date:  2010-03-12       Impact factor: 3.006

Review 2.  DSM-IV pain disorder in the general population. An exploration of the structure and threshold of medically unexplained pain symptoms.

Authors:  Christine Fröhlich; Frank Jacobi; Hans-Ulrich Wittchen
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2005-11-18       Impact factor: 5.270

3.  The proposed diagnosis of somatic symptom disorders in DSM-V to replace somatoform disorders in DSM-IV--a preliminary report.

Authors:  Joel Dimsdale; Francis Creed
Journal:  J Psychosom Res       Date:  2009-04-16       Impact factor: 3.006

4.  [New pain diagnosis in the German version of the ICD-10].

Authors:  W Rief; R-D Treede; U Schweiger; P Henningsen; H Rüddel; P Nilges
Journal:  Nervenarzt       Date:  2009-03       Impact factor: 1.214

Review 5.  Psychological approaches to origins and treatments of somatoform disorders.

Authors:  Michael Witthöft; Wolfgang Hiller
Journal:  Annu Rev Clin Psychol       Date:  2010       Impact factor: 18.561

Review 6.  Explaining medically unexplained symptoms-models and mechanisms.

Authors:  Winfried Rief; Elizabeth Broadbent
Journal:  Clin Psychol Rev       Date:  2007-07-17

Review 7.  Physical symptom disorder: a simpler diagnostic category for somatization-spectrum conditions.

Authors:  Kurt Kroenke
Journal:  J Psychosom Res       Date:  2006-04       Impact factor: 3.006

8.  Medically unexplained physical symptoms, anxiety, and depression: a meta-analytic review.

Authors:  Peter Henningsen; Thomas Zimmermann; Heribert Sattel
Journal:  Psychosom Med       Date:  2003 Jul-Aug       Impact factor: 4.312

9.  A systematic review of the epidemiology of somatisation disorder and hypochondriasis.

Authors:  Francis Creed; Arthur Barsky
Journal:  J Psychosom Res       Date:  2004-04       Impact factor: 3.006

10.  Efficacy of functional relaxation and patient education in the treatment of somatoform heart disorders: a randomized, controlled clinical investigation.

Authors:  Claas Lahmann; Thomas H Loew; Karin Tritt; Marius Nickel
Journal:  Psychosomatics       Date:  2008 Sep-Oct       Impact factor: 2.386

View more
  2 in total

1.  [Somatoform disorders: discussion on conceptual and diagnostic issues].

Authors:  C Hausteiner-Wiehle; P Henningsen
Journal:  Nervenarzt       Date:  2012-09       Impact factor: 1.214

2.  The Munich Diagnostic and Predictor Study of Dizziness: objectives, design, and methods.

Authors:  C Lahmann; P Henningsen; M Dieterich; R Feuerecker; C A Cyran; G Schmid
Journal:  J Neurol       Date:  2011-09-23       Impact factor: 4.849

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.